Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

Original reporting
Published Nov 5, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Collegium (COLL) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$COLLBullishMed
01

Why it matters

The earnings release provides fresh data on revenue growth, prescription trends, and capital allocation, offering traders a basis for short‑term positioning.

02

Market read

Earnings beat and buyback announcement give a clear catalyst for near‑term price movement.

03

What to watch

The $50M accelerated share repurchase could strain cash if future growth slows, and competition in ADHD space remains intense.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Collegium (COLL) is a specialty pharmaceutical company focused on ADHD and pain treatments. The Q3 2026 call highlighted record revenue, product growth, and a new share repurchase program.

Company-level read

Ticker impact

$COLLBullishHigh confidence
Context

Q3 2026 earnings call disclosed record $216.3M revenue, 3% YoY growth and reaffirmed full-year guidance plus a $50M accelerated share repurchase.

Expected impact

likely modest upside as the buyback and reaffirmed guidance support the share price

Evidence & confidence

The company delivered record revenue, confirmed guidance, and announced a sizable share repurchase, all fresh primary disclosures that can move the stock.

Market effects

Strengthens the ADHD pharmaceutical niche and may lift peers with similar product pipelines.

U.S. biotech sector may see modest uplift from the earnings beat.

Limited to investors focused on specialty pharma and ADHD treatments.

Counterpoint

Guidance reaffirmation may already be priced in; the modest revenue growth could disappoint if expectations were higher.

Key entities

  • Collegium

    U.S. listed specialty pharma firm (ticker COLL).

Related articles

$COLLMedAI 8/10

Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

$COLLMed

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

$COLLMed

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.

$COLLLow

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Genera